sabatolimab: Clinical Trials

17 trials of sabatolimab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 terminated, 2 active not recruiting, 2 completed, 2 withdrawn. 11 Phase 2, 10 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 211Terminated 8, Active not recruiting 2, Withdrawn 1
Phase 110Terminated 5, Completed 2, Withdrawn 2, Active not recruiting 1
Phase 31Terminated 1

Follow sabatolimab: new trials by email Literature Review of sabatolimab trials Research Report on sabatolimab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial
MBG-453 + Azacitidine - AML
Phase 1 / Phase 2Active not recruitingM.D. Anderson Cancer Center32024-12-302026-07-08
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
Sabatolimab, Magrolimab, Azacitidine - Myelodysplastic Syndromes, Acute Myeloid Leukemia
Phase 1 / Phase 2WithdrawnNovartis Pharmaceuticals2024-12-202024-04-11
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
decitabine, spartalizumab, sabatolimab - Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Phase 2Active not recruitingNovartis Pharmaceuticals332023-02-282026-09-22
STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS
MBG453, Azacitidine, Decitabine - Myelodysplastic Syndrome (MDS)
Phase 2TerminatedNovartis Pharmaceuticals392022-03-172025-10-16
MBG453 in Lower Risk MDS
MBG453 - Myelodysplastic Syndromes
Phase 2TerminatedMassachusetts General Hospital102022-01-272026-10-20
Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.
Sabatolimab, Azacitidine - Acute Myeloid Leukemia
Phase 1 / Phase 2TerminatedNovartis Pharmaceuticals242021-09-142025-10-16
Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS
MBG453, NIS793, canakinumab - Myelodysplastic Syndromes
Phase 1TerminatedNovartis Pharmaceuticals332021-06-182025-10-10
A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants
sabatolimab, azacitidine, venetoclax - Myelodysplastic Syndrome (MDS)
Phase 2TerminatedNovartis Pharmaceuticals202021-05-312025-10-09
Study of Select Combinations in Adults With Myelofibrosis
MBG453, NIS793, Spartalizumab - Primary Myelofibrosis, Myelofibrosis
Phase 1WithdrawnNovartis Pharmaceuticals2020-11-302021-03-04
A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy
MBG453, Venetoclax, Azacitidine - Acute Myeloid Leukemia
Phase 2TerminatedNovartis Pharmaceuticals902020-09-012026-01-13
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
Sabatolimab, Azacitidine, Placebo - Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Phase 3TerminatedNovartis Pharmaceuticals5302020-06-082026-01-13
Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM
MBG453 - Glioblastoma Multiforme
Phase 1CompletedSidney Kimmel Comprehensive Cancer Center at Johns Hopkins162020-02-182026-10-07
Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients
Ruxolitinib, Siremadlin, Crizanlizumab - Myelofibrosis
Phase 1 / Phase 2TerminatedNovartis Pharmaceuticals452019-09-262025-08-07
HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
HDM201, MBG453, Venetoclax - Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS)
Phase 1TerminatedNovartis Pharmaceuticals522019-06-242025-10-10
A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).
MBG453, Placebo, Hypomethylating agents - Myelodysplastic Syndromes
Phase 2TerminatedNovartis Pharmaceuticals1272019-06-042026-01-13
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
Decitabine, PDR001, MBG453 - Leukemia, Leukemia, Myeloid
Phase 1CompletedNovartis Pharmaceuticals2412017-07-062025-05-18
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
MBG453, PDR001, Decitabine - Advanced Malignancies
Phase 1 / Phase 2TerminatedNovartis Pharmaceuticals2522015-11-232023-12-06

Conditions studied

Myelodysplastic Syndromes (9)  ·  Leukemia, Myeloid, Acute (5)  ·  Leukemia, Myelomonocytic, Chronic (3)  ·  Primary Myelofibrosis (2)  ·  Bone Marrow Diseases (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Renal Cell (1)  ·  Glioblastoma (1)  ·  Hematologic Diseases (1)  ·  Leukemia (1)  ·  Leukemia, Myeloid (1)  ·  Melanoma (1)  ·  Myeloproliferative Disorders (1)  ·  Neoplasm, Residual (1)  ·  Polycythemia Vera (1)

Sponsors

Novartis Pharmaceuticals (14)  ·  M.D. Anderson Cancer Center (1)  ·  Massachusetts General Hospital (1)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)

Countries

United States (12)  ·  Italy (10)  ·  Spain (10)  ·  Germany (9)  ·  Australia (7)  ·  France (7)  ·  Canada (6)  ·  Japan (5)  ·  South Korea (5)  ·  Greece (4)  ·  Netherlands (4)  ·  Singapore (4)  ·  Switzerland (4)  ·  Taiwan (4)  ·  Turkey (Türkiye) (4)

Top investigators

Andrew Brunner, MD (1)  ·  Courtney DiNardo, MD (1)  ·  Lawrence Kleinberg, MD (1)

Results publications

PMID 33883177, PMID 37083373, PMID 38065203, PMID 39209782, PMID 40334082

NIH funding

2019 (5), 2018 (2), 2015 (1), 2016 (1)